tradingkey.logo
搜尋

Nautilus Biotechnology Inc

NAUT
添加自選
1.690USD
-0.080-4.52%
收盤 07-24 16:00美東報價延遲15分鐘
214.76M總市值
虧損本益比TTM

Nautilus Biotechnology Inc

1.690
-0.080-4.52%

關於 Nautilus Biotechnology Inc 公司

Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.

Nautilus Biotechnology Inc簡介

公司代碼NAUT
公司名稱Nautilus Biotechnology Inc
上市日期Aug 07, 2020
CEOPatel (Sujal)
員工數量155
證券類型Ordinary Share
年結日Aug 07
公司地址2701 Eastlake Ave East
城市SEATTLE
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編98102
電話12063332001
網址https://www.nautilus.bio/
公司代碼NAUT
上市日期Aug 07, 2020
CEOPatel (Sujal)

Nautilus Biotechnology Inc公司高管

名稱
名稱/職務
職務
持股
持股變動
Dr. Parag Mallick
Dr. Parag Mallick
Chief Scientist, Director
Chief Scientist, Director
20.69M
--
Mr. Farzad (Zod) Nazem
Mr. Farzad (Zod) Nazem
Independent Director
Independent Director
1.89M
--
Ms. Anna Mowry
Ms. Anna Mowry
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
85.50K
+11.70%
Mr. Kentaro (Ken) Suzuki
Mr. Kentaro (Ken) Suzuki
Chief Marketing Officer
Chief Marketing Officer
4.00K
--
Mr. Sujal Patel
Mr. Sujal Patel
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
--
--
Ms. Melissa B. Epperly
Ms. Melissa B. Epperly
Independent Director
Independent Director
--
--
Mr. Matthew S. (Matt) Mcilwain
Mr. Matthew S. (Matt) Mcilwain
Independent Director
Independent Director
--
--
Mr. Matthew L. Posard
Mr. Matthew L. Posard
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Karen Akinsanya
Ms. Karen Akinsanya
Independent Director
Independent Director
--
--
Mr. Nick Nelson
Mr. Nick Nelson
Chief Business Officer, Senior Vice President - Business Development
Chief Business Officer, Senior Vice President - Business Development
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Parag Mallick
Dr. Parag Mallick
Chief Scientist, Director
Chief Scientist, Director
20.69M
--
Mr. Farzad (Zod) Nazem
Mr. Farzad (Zod) Nazem
Independent Director
Independent Director
1.89M
--
Ms. Anna Mowry
Ms. Anna Mowry
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
85.50K
+11.70%
Mr. Kentaro (Ken) Suzuki
Mr. Kentaro (Ken) Suzuki
Chief Marketing Officer
Chief Marketing Officer
4.00K
--
Mr. Sujal Patel
Mr. Sujal Patel
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
--
--
Ms. Melissa B. Epperly
Ms. Melissa B. Epperly
Independent Director
Independent Director
--
--

常見問題

Nautilus Biotechnology Inc的前五大股東是誰?

Nautilus Biotechnology Inc的前五大股東如下:Dr. Parag Mallick

有多少機構持有Nautilus Biotechnology Inc(NAUT)的股份?

截至2026Q1,共有180家機構持有Nautilus Biotechnology Inc的股份,合計持有的股份價值約為60.30M,占公司總股份的47.66% 。與2025Q4相比,機構持股有所增加,增幅為1539418.00。
tradingkey.logo
風險提示:我們的網站和行動應用程式僅提供關於某些投資產品的一般資訊。Finsights 不提供財務建議或對任何投資產品的推薦,且提供此類資訊不應被解釋為 Finsights 提供財務建議或推薦。
投資產品存在重大投資風險,包括可能損失投資的本金,且可能並不適合所有人。投資產品的過去表現並不代表其未來表現。
Finsights 可能允許第三方廣告商或關聯公司在我們的網站或行動應用程式的任何部分放置或投放廣告,並可能根據您與廣告的互動情況獲得報酬。
© 版權所有: FINSIGHTS MEDIA PTE. LTD. 版權所有